Wellness Journey Center NZ

05/04/2026

Never judge

03/04/2026

Did you know the Japanese use blood type to ascertain our psychological profile called The Japanese ketsueki-gata (血液型) personality theory originated in the 20th Century.

The first Dr was in 1916 Dr Kimata Hara who published early research suggesting a link between blood groups and temperament.

Furukawa's (in 1927) Inspiration who was a Psychologist who published "Ketsuekigata ni yoru Kish*tsu no Kenkyū" ("The Study of Temperament Through Blood Type"), formally introducing the theory to the public.

Furukawa drew from Hippocrates' ancient Greek humoral theory, which classified temperaments (sanguine, phlegmatic, choleric, melancholic) based on bodily fluids.
He proposed blood type could objectively replace the four humors for studying temperament, merging physiological and psychological dimensions .

The 1970s RevivalThe theory died out after Furukawa's death but was revived in the 1970s by:Masahiko Nomi – A journalist with no medical background who published bestselling books on blood type and personality
Tosh*taka Nomi (his son) – Continued promoting the theory and established the Institute of Blood Type Humanics:
Why It Stuck : Nomi's books became self-help guides for romance and business, transforming ketsueki-gata into a cultural phenomenon despite lacking scientific evidence.
Today it influences dating, hiring, and consumer products across Japan, Korea, and Taiwan

Note: Furukawa's original research was criticized for small sample sizes and lack of empirical evidence, and modern studies confirm no credible link between blood type and personality

01/04/2026

10/03/2026

Chronic stress is making us fat

06/03/2026

Send sun to ripen my tomatoes

01/03/2026

So I made deodorant again. The recipe is in the photo. Use a double boiler to melt the ingredients

28/02/2026

The viral gelatine thing. Cook apple add psyllium and gelatin ( or agar). Set. Nice sweet treat and healthy for your gut

28/02/2026

Know your worth always

28/02/2026

Please reach out. Everything is solvable. You are loved and you matter to the world

28/02/2026

Enemas, nudity and witches... 👀

Questions a naturopath gets ( sometimes)

1. Are you a naturist? 🙄
It’s naturOPATH, so no, but my houseplants are.

2. Does this rash look weird to you? 😳
I have just met you, and 40% of your epidermis - yes, that is weird.

3. If I see you, can I stop seeing my doctor? 👩‍⚕️
No, I complement, I don’t replace. Break up with Dr Google first - keep your actual doctor.

4. You would totally advocate for at-home enemas, hey? 💩
Friends don’t let friends DIY colonics. Hydration, fibre and bitters, first.

5. If it is natural, it’s safe, right?
Arsenic would beg to differ; dose and context matter.

6. Will these bitters cancel out last night’s gin binge? 🍸
Your liver is an employee, not a magician...

7. Are you a witch? - Tbh I am ok with this one, because, yes - absolutely. 🧙‍♀️

21/02/2026

🔥 Blindness is now the #2 reason people are suing some GLP-1 manufacturers. (Stomach Paralysis is #1)

GLP-1 medications, or glucagon-like peptide-1 receptor agonists, are a class of drugs primarily used to manage type 2 diabetes by mimicking the GLP-1 hormone to regulate blood sugar. They're also widely prescribed for weight loss due to their appetite-suppressing effects.

Common Examples: Popular GLP-1 drugs include semaglutide (Ozempic for diabetes, Wegovy for weight loss), liraglutide (Victoza for diabetes, Saxenda for weight loss), dulaglutide (Trulicity), and exenatide (Byetta, Bydureon).

Some, like tirzepatide (Mounjaro), act on both GLP-1 and GIP receptors for enhanced effects on blood sugar and weight.

Higher-dose versions like Wegovy are FDA-approved specifically for chronic weight management in obesity.
How They Work: These injectables (weekly or daily) boost insulin release, slow digestion, and signal fullness to the brain, lowering A1C levels and promoting 8-15% body weight loss in trials.

They're often paired with diet and exercise; stopping them typically leads to weight regain.

“A federal panel of judges agreed to centralize litigation against manufacturers of GLP-1 drugs, alleging that they have caused non-arteritic anterior ischemic optic neuropathy (NAION). This is the second-highest category for lawsuits against GLP-1 manufacturers behind gastroparesis, also known as stomach paralysis. This comes as HHS recently announced it is working to expand access to the medications as part of the response to the ongoing obesity epidemic in the United States, where over 40% of American adults are obese.

A 2025 study of 139,000 diabetes patients over the age of 66 found that those who received GLP-1 drugs for the treatment of diabetes were twice as likely to develop neovascular age-related macular degeneration (nAMD) than the control group. Another 2025 study concluded users of GLP-1 drugs were 68.6 times more likely to develop NAION and eight times more likely to develop diabetic retinopathy than those taking empagliflozin, exenatide, insulin, or metformin.” - Credit: The Highwire

- Dr. Doug Corrigan